| HOME >> BIOLOGY >> TECHNOLOGY |
SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has appointed Robert De Jager, M.D., as chief medical officer, reporting to Jerry McMahon, Ph.D., Poniard's chairman and CEO.
"Dr. De Jager has built an extensive and successful professional career in developing and registering novel cancer therapeutics, and we expect that he will play a critical role in successfully preparing the global oncology marketplace for our picoplatin drug candidate," said Dr. McMahon. "Picoplatin has important potential advantages over currently available platinum agents, including a favorable safety profile and the ability to potentially overcome platinum resistance. Dr. De Jager's experience will be invaluable to Poniard to ensure that picoplatin meets the market needs."
"I am excited to join the experienced team at Poniard focused on moving picoplatin forward into product approval," said Dr. De Jager. "Based on picoplatin's demonstrated activity to date, I believe in picoplatin's likely regulatory and technical success as a therapeutic for small cell lung cancer, metastatic colorectal cancer and hormone-refractory prostate cancer and other indications."
Dr. De Jager joins Poniard from the biotechnology company Kosan
Biosciences, where he served as senior vice president, chief medical
officer. Prior to his position at Kosan Biosciences, Dr. De Jager served as
chief medical officer and vice president, Clinical Research and Development
for Conforma Therapeutics Corporation, a biotechnology company acquired by
Biogen Idec Inc. At Biogen Idec, he was senior director, Oncology Research
and Development. Earlier in his
'/>"/>
| SOURCE Poniard Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |